Royalty Report: Drugs, Pain, Disease – Collection: 390159


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pain
  • Disease
  • Migraine
  • Therapeutic
  • Technical Know How

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 390159

License Grant
Licensor granted Virgin Island Licensee exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists for the treatment of CGRP-mediated disorders, including non-migraine indications. This includes in-licensed patents and patent applications in the U.S. and foreign countries directed to CGRP receptor antagonists.
License Property
The portfolio included the lead candidate HTL0022562, referred to as BHV-3100, which had advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. BHV-3100, the most advanced candidate in a portfolio of novel, small-molecule CGRP receptor antagonists being developed. BHV-3100, previously known as HTL0022562, was developed successfully through preclinical trials by Licensor and demonstrated promising and differentiated properties in target CGRP-mediated disorders.

The patents and patent applications disclose novel compounds, pharmaceutical compositions and methods of treating various diseases including those other than migraine such as pain, hot flashes, cluster headache and other CGRP-mediated cerebrovascular and vascular disorders. The patents and patent applications include, for example, U.S. Patents 9,808,457 and 10,300,056.

U.S. Patent 9,808,457 – CGRP receptor antagonists
U.S. Patent 10,300,056 – CGRP receptor antagonists

Calcitonin gene related peptide (CGRP) receptor antagonism, glutamate modulation, myeloperoxidase ('MPO') inhibition, Kv7 Ion Channel Activators (Kv7), and Myostatin.

Field of Use
The rights granted is for for the treatment of CGRP-mediated disorders, including non-migraine indications.

CGRP stands for calcitonin gene-related peptide, and it is a protein that is released around the brain. When CGRP is released, it causes intense inflammation in the coverings of the brain (the meninges), and for most migraine patients, causes the pain of a migraine attack.

Licensee is a biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders.

IPSCIO Record ID: 220108

License Grant
The Licensee has entered into a Settlement and License Agreement with the Swiss Licensor.  The Licensee has received a non-exclusive license to the Licensors CGRP (calcitonin gene-related peptide) patent portfolio to develop, manufacture and commercialize eptinezumab for migraine, in the United States and worldwide, excluding Japan and Korea.
License Property
Eptinezumab (formerly ALD403) is an experimental drug being developed for the treatment of migraine. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is in Phase III clinical trials as of August 2017.

The Agreement resolves the Licensees appeal following opposition proceedings before the European Patent Office related to the Licensors European Patent No. 1957106 B1, with respect to calcitonin gene-related peptide antagonist antibodies.

Field of Use
The License is to manufacture and commercialize eptinezumab, a product candidate for migraine prevention targeting CGRP.

IPSCIO Record ID: 279382

License Grant
Licensor grants an exclusive license under Licensor Know-How and Licensed Patents to make, have made, use, sell, offer for sale, and import Compound and Product in the Field in theTerritory.
License Property
Licensor has certain intellectual property rights relating to its non-selective AMPA/Kainate receptor antagonist.

The patents include, but are not limited to Excitatory amino acid receptor antagonists, and, Process for preparing isoquinoline compounds, and, Synthesis of cis-decahydroisoquinoline-3-carboxylic acids.

AMPA/kainate, or AK, antagonist assets including its lead drug candidate, tezampanel, and NGX426.

Tezampanel has a range of effects which may be useful for medicinal purposes, as well as its applications in scientific research. It suppresses both the withdrawal symptoms from morphine and other opioids, and the development of tolerance,as well as having and analgesic effects in its own right. It also has anxiolytic effects in animal studies and has been suggested as a candidate for the treatment of anxiety in humans.

Field of Use
The Field means all human therapeutic indications including, but not limited to, migraine, post-operative pain and epilepsy.

IPSCIO Record ID: 324861

License Grant
INVENTORS irrevocably sell, transfer and assign to Licensee all of the INVENTORS’ Patent Rights and INVENTORS’ Technology Rights, including the right to sublicense any or all of such rights, to make, have made, use, have used, sell, and have sold the Drug Technology in the Field.
License Property
Patents relate to neuroprotective and anticonvulsant small-molecule drug technology.

Assets to be Purchased All patents, patents pending, trademarks, research and development materials, raw materials, (including compounds in storage), chemical entities in the patent estate namely AND-302; AND-378; AND-383; AND-380; and AND-407, also referenced in and by the following (the “Intellectual Property”) (a.) PCT WO2012/074784 A2 – “Novel Fluorinated Sulfamides Exhibiting Neuroprotective Action and Their Method of Use”; (b.) US Patent 8,609,849 – “Novel Hydroxylated Sulfamides Exhibiting Neuroprotective Action and Their Method of Use”; (c.) All compounds contained in an original provisional patent relating to piperidine chemistry for refractory epilepsy, namely AND-378 and AND-383; and (d.) All technology described in the Phase 2 SBIR Research Strategy pertaining to the aforementioned body of intellectual property and technology (the Intellectual Property or IP).

8,609,849 – Hydroxylated sulfamides exhibiting neuroprotective action and their method of use

Field of Use
The novel class of anticonvulsant drugs is designed to treated refractory epilepsy and neuropathic pain.

“Field” means the human use of the Manufactured Products in pharmaceutical preparations, including but not limited to per os (oral tablets or capsules), intravenous, topical skin, intranasal cavaties, anal suppositories, or subcutaneous implants.

The field of use is for the treatment of neurological disorders.

Neurological disorders are diseases of the central and peripheral nervous system.  These disorders include epilepsy, Alzheimer disease and other dementias, cerebrovascular diseases including stroke, migraine and other headache disorders, multiple sclerosis, Parkinsons disease, neuroinfections, brain tumours, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.